Treatment Stories
934 articles
A Year in Review: 2022 in Research
What progress was made in pancreatic treatment and screening? Learn about the major pancreatic cancer developments of 2022.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Advances in Pancreatic Neuroendocrine Tumor (PNET) Treatments
Dr. Diane Reidy-Lagunes outlines the current state of treatments for pancreatic neuroendocrine tumors (PNETs).
New Neoadjuvant Treatment in Trials
Dr. Brian Wolpin provides an analysis of the latest data on a new neoadjuvant treatment for tumors that can be removed.
A Look Back at Research in 2024
Research in 2024 focused on personally tailored treatments, countering the most difficult effects of pancreatic cancer, and clinical trials.
Stereotactic Body Radiation Therapy (SBRT) for Select Pancreatic Cancer Patients
Stereotactic body radiation therapy (SBRT) is increasingly being used to treat locally advanced pancreatic cancer, and make it surgically removable.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
A Combination of Neoadjuvant Chemotherapy and Radiation Shows Promise
Dr. Alok Khorana discusses the results of clinical trials of neoadjuvant chemotherapy and radiation to make surgery more effective.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
New Guidelines on the Use of Radiation for Pancreatic Cancer Treatment
New clinical guidelines from the American Society for Radiation Oncology will help clarify the best uses of radiation treatment for pancreatic cancer.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
Aiming to Improve Immunotherapy for Pancreatic Cancer
Dr. Deirdre Cohen discusses clinical trials that aim to improve the effectiveness of immunotherapy for pancreatic cancer.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.